Pharmacological Treatment of Rett Syndrome With Statins

Overview

This is a phase 2 , open label, dose escalating study of Lovastatin in Rett syndrome.

Full Title of Study: “Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2016

Detailed Description

Excess neuronal cholesterol plays a role in the pathophysiology of Rett syndrome(RTT) and the investigators hypothesise that inhibition of cholesterol synthesis in the CNS will reduce neuronal cholesterol and lead to improvement in Rett syndrome related symptoms. Goal: To determine the optimal dosing regiment of Lovastatin for patients with RTT and to identify the most appropriate primary outcome measure for the subsequent Phase 3 study. Phase 2, dose escalation study. Primary outcome: Gait speed Secondary outcomes: respiratory function, cognition, EEG (encephalopathy), Rett syndrome severity scale, neurodevelopmental assessment (QOL) 20 ambulatory female patients with genetically confirmed.

Interventions

  • Drug: Lovastatin
    • dose escallating

Arms, Groups and Cohorts

  • Experimental: Open label
    • Treatment with Lovastatin, dose escalating trial according to the following schedule: 10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Gait Velocity as Measured by GAITRite System
    • Time Frame: During final week of treatment, week 32
    • To perform quantitative gait assessment using a computerized walkway with embedded pressure sendors (GAIT rite)

Secondary Measures

  • Visual Memory Novelty Score as Assessed by TobiiTX 300 Eyetracking System
    • Time Frame: final week of treatment, Week 32
    • Novelty score is considered a composite measure of visual memory.Test is a standardized neuropsychological test( “Rose test”) adapted for eye tracking system. The present study made use of a well-established battery of “visual paired comparison” problems .There were nine problems: five using achromatic photos of faces and four using multicolored abstract patterns paired stimuli , separated by 23°. For each problem, two identical stimuli are briefly presented side by side for familiarization, then the familiar and a new one are paired on test Recognition(memory) is indexed by a novelty score (percentage of looking to the novel target on test). Higher novelty scores were related to better recognition (index of better memory) Scores range from 0.0-1.0 (0-100%) and indicate 1) more overall looking at novel target and (2) more fixations to novel targets. Score of .5 (50%) indicates looking “by change” only with no recognition.

Participating in This Clinical Trial

Inclusion Criteria

  • Females patients, – Genetically confirmed RTT, – Ambulatory. Exclusion Criteria:

  • Presence of co morbid non-Rett related disease, – History of adverse reaction/hypersensitivity to statins, – Levels of aspartate-amino trans-ferase (AST), alanine-amino transferase (ALT) or creatine kinase (CK) triple the normal values, – Active liver disease, – Concomitant use of strong CYP3A4 inhibitors, – Condition predis-posing to renal failure secondary to rhabdomyolysis (scoliosis surgery within 6 months), – Oral contraceptives use.

Gender Eligibility: Female

Minimum Age: 3 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Montefiore Medical Center
  • Collaborator
    • Rett Syndrome Research Trust
  • Provider of Information About this Clinical Study
    • Principal Investigator: Aleksandra Djukic, Professor of Clinical Neurology, Director, Tri State Rett Syndrome Center – Montefiore Medical Center
  • Overall Official(s)
    • Aleksandra Djukic, MD PhD, Principal Investigator, Montefiore Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.